173 related articles for article (PubMed ID: 12505696)
1. The enzymatic inactivation of the fatty acid amide class of signaling lipids.
Cravatt BF; Lichtman AH
Chem Phys Lipids; 2002 Dec; 121(1-2):135-48. PubMed ID: 12505696
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
3. A second fatty acid amide hydrolase with variable distribution among placental mammals.
Wei BQ; Mikkelsen TS; McKinney MK; Lander ES; Cravatt BF
J Biol Chem; 2006 Dec; 281(48):36569-78. PubMed ID: 17015445
[TBL] [Abstract][Full Text] [Related]
4. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
Cravatt BF; Demarest K; Patricelli MP; Bracey MH; Giang DK; Martin BR; Lichtman AH
Proc Natl Acad Sci U S A; 2001 Jul; 98(16):9371-6. PubMed ID: 11470906
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory lipids in plants: plant fatty acid amides and the human endocannabinoid system.
Gertsch J
Planta Med; 2008 May; 74(6):638-50. PubMed ID: 18275004
[TBL] [Abstract][Full Text] [Related]
6. Functional disassociation of the central and peripheral fatty acid amide signaling systems.
Cravatt BF; Saghatelian A; Hawkins EG; Clement AB; Bracey MH; Lichtman AH
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10821-6. PubMed ID: 15247426
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
Cravatt BF; Lichtman AH
Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
[TBL] [Abstract][Full Text] [Related]
8. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.
Cravatt BF; Giang DK; Mayfield SP; Boger DL; Lerner RA; Gilula NB
Nature; 1996 Nov; 384(6604):83-7. PubMed ID: 8900284
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid amide hydrolase inhibitors--progress and potential.
Khanna IK; Alexander CW
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):545-58. PubMed ID: 21631410
[TBL] [Abstract][Full Text] [Related]
11. FAAH and anandamide: is 2-AG really the odd one out?
Di Marzo V; Maccarrone M
Trends Pharmacol Sci; 2008 May; 29(5):229-33. PubMed ID: 18394720
[TBL] [Abstract][Full Text] [Related]
12. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
Snider NT; Walker VJ; Hollenberg PF
Pharmacol Rev; 2010 Mar; 62(1):136-54. PubMed ID: 20133390
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task.
Varvel SA; Cravatt BF; Engram AE; Lichtman AH
J Pharmacol Exp Ther; 2006 Apr; 317(1):251-7. PubMed ID: 16352706
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fatty acid amides in the carrageenan-induced paw edema model.
Wise LE; Cannavacciulo R; Cravatt BF; Martin BF; Lichtman AH
Neuropharmacology; 2008 Jan; 54(1):181-8. PubMed ID: 17675189
[TBL] [Abstract][Full Text] [Related]
15. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase.
Clement AB; Hawkins EG; Lichtman AH; Cravatt BF
J Neurosci; 2003 May; 23(9):3916-23. PubMed ID: 12736361
[TBL] [Abstract][Full Text] [Related]
16. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility.
Maccarrone M; Valensise H; Bari M; Lazzarin N; Romanini C; Finazzi-Agrò A
J Immunol; 2001 Jun; 166(12):7183-9. PubMed ID: 11390466
[TBL] [Abstract][Full Text] [Related]
17. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
Bisogno T; Melck D; De Petrocellis L; Bobrov MYu ; Gretskaya NM; Bezuglov VV; Sitachitta N; Gerwick WH; Di Marzo V
Biochem Biophys Res Commun; 1998 Jul; 248(3):515-22. PubMed ID: 9703957
[TBL] [Abstract][Full Text] [Related]
18. Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases.
Pillarisetti S; Alexander CW; Khanna I
Drug Discov Today; 2009 Dec; 14(23-24):1098-111. PubMed ID: 19716430
[TBL] [Abstract][Full Text] [Related]
19. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides.
Patricelli MP; Cravatt BF
Vitam Horm; 2001; 62():95-131. PubMed ID: 11345902
[TBL] [Abstract][Full Text] [Related]
20. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'.
Maurelli S; Bisogno T; De Petrocellis L; Di Luccia A; Marino G; Di Marzo V
FEBS Lett; 1995 Dec; 377(1):82-6. PubMed ID: 8543025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
